Clinical trials: Immunotoxicity, open to volunteers
Melanoma, Immunotoxicity
Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma Management
Management of melanoma is based on primary excision of the tumor. In cases of melanoma with poor prognosis criteria, or when it is locally advanced or metastatic, there is an indication for the implementation of adjuvant therapy…
- Trial name
- APiTOXMM (NCT06627595)
- Testing
- Immunotherapy
- Where
- 2 sites in France
- Volunteers
- 160 people
- Sponsor
- University Hospital, Montpellier
Cytokine Release Syndrome
Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy
This is an interventional study to evaluate the use of CTO1681 in preventing or reducing CAR T-cell-induced toxicities like cytokine release syndrome (CRS).
- Trial name
- NCT05905328
- Testing
- CTO1681 10 µg, CTO1681 20 μg, CTO1681 30 μg
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- CytoAgents, Inc.
Autoimmunity, Cancer
Autoimmunity After Checkpoint Blockade
The purpose of this study is to better understand how the treatment of cancer with immune checkpoint inhibitors (ICI) leads to the development of autoimmunity.
- Conditions
- Autoimmunity, Cancer, Immunotoxicity, Oncology
- Trial name
- NCT04119713
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Abramson Cancer Center at Penn Medicine